Item 8.01 Other Events.

Greenwich LifeSciences, Inc. (the "Company") is confirming the following in light of the interest in both of its GP2 Phase IIb clinical trial and Phase III clinical trial, Flamingo-01:

The Food and Drug Administration (the "FDA") reviewed the Company's Phase IIb clinical data before the commencement of the Flamingo-01 clinical trial. The first US sites were activated in the 3rd Quarter of 2022 and the clinical trial is currently enrolling patients and has been screening and treating patients since the 4th Quarter of 2022. DTH skin tests are being conducted and blood samples are being collected to assess immune response. The Company is planning an expansion of the Flamingo-01 clinical trial into Europe.

The abstract and poster at the upcoming AACR conference, scheduled for the Phase II and Phase III Clinical Trials in Progress poster session on April 17, 2023, is focused only on the design of Flamingo-01 and is intended for discussions with clinicians.

-2-

© Edgar Online, source Glimpses